Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells

Clinical and Experimental Immunology

Volumn 168, Issue 2, 2012, Pages 192-199

  Curd, L M ^a   Favors, S E ^a   Gregg, R K ^a,b  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

IL 22; NK cells; Pancreatic cancer; STAT 3; Th17

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 22; PROTEIN BCL XL; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ARTICLE; CANCER CELL; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; NATURAL KILLER CELL; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL FACTOR; TUMOR GROWTH;

APOPTOSIS; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKINS; KILLER CELLS, NATURAL; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 84859244400     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04570.x     Document Type: Article

References (41)

1. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010; 184:1630-41.
2. Ankathatti MM, Deng Y, Mulligan SH etal. Th17 and Th17-stimulated CD8(+) T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother 2011; 60:1473-84.
3. Gnerlich JL, Mitchem JB, Weir JS etal. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 2010; 185:4063-71.
4. Martin-Orozco N, Muranski P, Chung Y etal. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31:787-98.
5. Muranski P, Boni A, Antony PA etal. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112:362-73.
6. Wang L, Yi T, Kortylewski M etal. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206:1457-64.
7. Liu J, Duan Y, Cheng X etal. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011; 407:348-54.
8. Iida T, Iwahashi M, Katsuda M etal. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 2011; 25:1271-7.
9. Zhou P, Sha H, Zhu J. The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J Int Med Res 2010; 38:611-19.
10. Zhang JP, Yan J, Xu J etal. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50:980-9.
11. Tartour E, Fossiez I, Joyeux A etal. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999; 59:3698-704.
12. Numasaki M, Watanabe M, Suzuki T etal. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175:6177-89.
13. Xie MH, Aggarwal S, Ho WH etal. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000; 275:31335-9.
14. Kotenko SV, Izotova LS, Mirochnitchenko OV etal. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 2001; 276:2725-32.
15. Radaeva S, Sun R, Pan HN etal. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004; 39:1332-42.
16. Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol 2010; 107:1-29.
17. Nagalakshmi ML, Rascle A, Zurawski S etal. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004; 4:679-91.
18. Hoegl S, Bachmann M, Scheiermann P etal. Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol 2011; 44:369-76.
19. Shioya M, Andoh A, Kakinoki S etal. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas 2008; 36:197-9.
20. Aggarwal S, Xie MH, Maruoka M etal. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 2001; 21:1047-53.
21. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000; 164:1814-19.
22. Dumoutier L, Van Roost E, Colau D, Renauld JC. Human interleukin-10 T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 2000; 97:10144-9.
23. Levy DE, Darnell JE. STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651-62.
24. Aggarwall BB, Sethi G, Ahn KS etal. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 2006; 1091:151-69.
25. Wang T, Niu G, Kortylewski M etal. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54.
26. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT-3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51.
27. Rivat C, Rodrigues S, Bruyneel E etal. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)-and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 2005; 65:195-202.
28. Aggarwal BB, Kunnumakkara AB, Harikumar KB etal. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 2009; 1171:59-76.
29. Eriksen KW, Kaltoft K, Mikkelsen G etal. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemia Sezary cells. Leukemia 2001; 15:787-93.
30. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-96.
31. Ogata H, Chinen T, Yoshida T etal. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production. Oncogene 2006; 25:2520-30.
32. Kinjyo I, Inoue H, Hamano S etal. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med 2006; 203:1021-31.
33. Gelebart P, Zak Z, Dien-Bard J etal. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 2011; 4:9-19.
34. Bard JD, Gelebart P, Anand M etal. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 2008; 22:1595-603.
35. Zhang W, Chen Y, Wei H etal. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008; 14:6432-9.
36. Prabhala RH, Pelluru D, Fulciniti M etal. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115:5385-92.
37. Niu G, Wright KL, Huang M etal. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21:2000-8.
38. Jiang R, Tan Z, Deng L etal. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54:900-9.
39. Halak BK, Maguire HC Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as non-tumor antigen present at the tumor site. Cancer Res 1999; 59:911-17.
40. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10:554-67.
41. Lee JC, Lee KM, Ahn YO etal. A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1. Tumori 2011; 97:350-7.